Can-Fite Biopharma Ltd - ADR
CANF
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.43M
Close$
$0.01
99.6% downside
Current Fair Value
99.6% downsideOvervalued by 99.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.43 Million |
|---|---|
| Enterprise Value | $10.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.08 |
| Beta | 0.02 |
| Outstanding Shares | 3,711,022 |
Return
| Return on Equity | -196.77% |
|---|---|
| Return on Assets | -118.60% |
| Return on Invested Capital | -166.93% |
Valuation & Multiples
| P/E Ratio | -0.29 |
|---|---|
| PEG | 5.13 |
| Price to Sales | - |
| Price to Book Ratio | 1.85 |
| Enterprise Value to Revenue | 25.92 |
| Enterprise Value to EBIT | -1.08 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 8, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$300,000
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$202,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.62%▲ 0.05% |
|---|---|
| Total Invested | $271,361▼ 71.51% |
| Investors Holding | 14▼ 1.00% |
ESG Score
No data
About Can-Fite Biopharma Ltd
5 employees
CEO: Pnina Fishman Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, v...